source
- FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinomaonclive · 2mo ago↗ source
- STAT+: Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drugCapricor Therapeutics has accused Nippon Shinyaku and its U.S. subsidiary of botching the rollout of a Duchenne muscular dystrophy treatment.STAT · 2mo ago↗ source
- UT MD Anderson Shares Latest Research BreakthroughsThe University of Texas MD Anderson Cancer Center released recent oncology research highlights.onclive · 2mo ago↗ source